Variant · Snv
EGFR S492R
CI-VAR-00004078Explore in graph →NP_005219.2:p.Ser492ArgNM_005228.4:c.1476C>AClinVar 376341 CIViC 453 rs1057519860
Curated evidence
Evidence by cancer (9 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22270724
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Colorectal Neoplasm7 | ||||||||
| EGFR S492R | Cetuximab | Predictive | C | Supports Resistance | 4 | accepted | EID717In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro… (full text at CIViC) PMID 22270724 · Montagut et al., 2012 · Open in CIViC | civic |
| EGFR S492R | Cetuximab | Predictive | D | Supports Resistance | 4 | accepted | EID1080In this preclinical study of the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but re… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available